Evidence map›Paper›PMID 37596461›Full record

Trial reportScientific reports2023

Estimation of treatment effect in presence of noncompliance and competing risks: a simulation study.

Malihe Safari, Habib Esmaeili, Hossein Mahjub, Ghodratollah Roshanaei

Abstract readRandomized Controlled Trial
In one paragraph

Trial report in Scientific reports, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Malihe SafariDepartment of Biostatistics, School of Medicine, Arak University of Medical Sciences, Arak, Iran.
Habib EsmaeiliStaburo GmbH, Munich, Germany.
Hossein MahjubDepartment of Biostatistics, Faculty of Public Health, Research Center for Health Sciences, Hamadan University of Medical Sciences, Hamadan, Iran.
Ghodratollah RoshanaeiDepartment of Biostatistics, School of Public Health, Modeling of Noncommunicable Diseases Research Center, Hamadan University of Medical Sciences, Hamadan, Iran. gh.roshanaei@umsha.ac.ir.ORCID http://orcid.org/0000-0002-3547-9125

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

A randomized controlled trial is commonly designed to assess the treatment effect in survival studies, in which patients are randomly assigned to the standard or the experimental treatment group. Upon disease progression, patients who have been randomized to standard treatment are allowed to switch to the experimental treatment. Treatment switching in a randomized controlled trial refers to a situation in which patients switch from their randomized treatment to another treatment. Often, the switchis from the control group to the experimental treatment. In this case, the treatment effect estimate is adjusted using either convenient naive methods such as intention-to-treat, per-protocol or advanced methods such as rank preserving structural failure time (RPSFT) models. In previous simulation studies performed so far, there was only one possible outcome for patients. However, in oncology in particular, multiple outcomes are potentially possible. These outcomes are called competing risks. This aspect has not been considered in previous studies when determining the effect of a treatment in the presence of noncompliance. This study aimed to extend the RPSFT method using a two-dimensional G-estimation in the presence of competing risks. The RPSFT method was extended for two events, the event of interest and the competing event. For this purpose, the RPSFT method was applied based on the cause-specific hazard approach, the result of which is compared to the naive methods used in simulation studies. The results show that the proposed method has a good performance compared to other methods.

Indexed as

IntentionPatient ComplianceComputer SimulationDisease ProgressionHumansMedical Oncology

Identifiers

PMID37596461
PMCPMC10439130

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.